Curaleaf Boosts Hostile Offer for Aurora Cannabis
Curaleaf increased the implied value of its unsolicited offer for Aurora Cannabis and enlarged the cash portion, now about a fifth of the mix.
On Tuesday the Stamford, Connecticut‑based firm filed a Notice of Variation, Change and Extension with Canadian regulators and a new SEC registration statement, moving the expiry to early December.
The revised offer raises the total implied value by roughly 25 % and expands the cash component, while lifting the cap price that sets the maximum payment per Aurora share.
Aurora’s board rejected the initial bid in mid‑August and told shareholders to take no action while its special committee reviews the enhanced terms.
Paying mostly in Curaleaf subordinate voting shares will dilute existing Curaleaf investors, reducing their proportional ownership in the combined company.
Curaleaf calculates the premium using its closing share price on the Toronto Stock Exchange, marking a sizeable premium over Aurora’s unaffected price and a larger premium once cash and at‑market equity issuances are excluded.
Curaleaf also notes that the higher cap price means the maximum payment per share will move with its own share price, a detail set out in the offer documents.
Because Aurora has refused standard due‑diligence access, Curaleaf’s synergy estimates rely on public data and remain untested against Aurora’s internal figures.
Cannabis integrations typically achieve savings from head‑office functions, procurement and technology, as regulatory limits restrict cross‑border production consolidation.
Curaleaf’s subordinate voting shares trade on the Toronto Stock Exchange and over the counter in the United States, whereas Aurora shareholders currently hold a stock with broader exchange access.
Canadian takeover rules require a minimum deposit period, a tender threshold of more than half of the outstanding shares not owned by the bidder, and an additional extension period once that threshold is met, shaping the early‑December deadline.
Hostile bids are rare in the cannabis sector, which has preferred negotiated mergers or distressed asset sales.
Curaleaf disputed Aurora’s request for pro forma statements in its original offering circular but provided them voluntarily, noting they are based on assumptions and public information.
Chairman and CEO Boris Jordan said the enhancement reflects a commitment to a fair, open process and a value‑creation opportunity, while Aurora’s board has not yet issued a formal response.
Tax consequences may arise for Canadian and U.S. taxpayers from share exchanges, and shareholders are directed to the offer documents and their advisers for details.
The near‑term milestones include Aurora’s special committee response, a directors’ circular on the revised bid, potential further Curaleaf amendments, and the final tender count as the December deadline approaches.
No share‑price reaction was reported and the October releases did not disclose how many Aurora shares have been tendered, a key indicator of market traction.
